Literature DB >> 33634555

Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes.

Yanyan Miao1, Qianqian Gao1, Menghan Mao1, Chao Zhang1, Liqun Yang1, Yang Yang2, Da Han1.   

Abstract

The ability to regulate membrane protein abundance offers great opportunities for developing therapeutic sites for various diseases. Herein, we describe a platform for the targeted degradation of membrane-associated proteins using bispecific aptamer chimeras that bind both the cell-surface lysosome-shuttling receptor (IGFIIR) and the targeted membrane-bound proteins of interest. We demonstrate that the aptamer chimeras can efficiently and quickly shuttle the therapeutically relevant membrane proteins of Met and PTK-7 to lysosomes and degrade them through the lysosomal protein degradation machinery. We anticipate that our method will provide a universal platform for the use of readily synthesized aptamer materials for biochemical research and potential therapeutics.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  aptamers; membrane-associated proteins; protein degradation; receptors; therapeutic strategies

Year:  2021        PMID: 33634555     DOI: 10.1002/anie.202102170

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  7 in total

Review 1.  Major Advances in Emerging Degrader Technologies.

Authors:  Hang Luo; Li Wu; Yujian He; Chong Qin; Xinjing Tang
Journal:  Front Cell Dev Biol       Date:  2022-06-22

Review 2.  Aptamer-Based Cancer Cell Analysis and Treatment.

Authors:  Limei Wu; Yutong Zhang; Zhimin Wang; Yue Zhang; Jianmei Zou; Liping Qiu
Journal:  ChemistryOpen       Date:  2022-10       Impact factor: 2.630

Review 3.  Cancer immunomodulation using bispecific aptamers.

Authors:  Brian J Thomas; David Porciani; Donald H Burke
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-10       Impact factor: 8.886

Review 4.  Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.

Authors:  Sinan Ma; Jianai Ji; Yuanyuan Tong; Yuxuan Zhu; Junwei Dou; Xian Zhang; Shicheng Xu; Tianbao Zhu; Xiaoli Xu; Qidong You; Zhengyu Jiang
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

Review 5.  Recent advances in aptamer-based targeted drug delivery systems for cancer therapy.

Authors:  Fei Gao; Jianhui Yin; Yan Chen; Changyong Guo; Honggang Hu; Jiacan Su
Journal:  Front Bioeng Biotechnol       Date:  2022-08-16

6.  Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin.

Authors:  Lin Zhang; Ling Li; Xia Wang; Huimin Liu; Yibin Zhang; Tiantian Xie; Hui Zhang; Xiaodong Li; Tianhuan Peng; Xing Sun; Jing Dai; Jing Liu; Wencan Wu; Mao Ye; Weihong Tan
Journal:  Mol Ther Nucleic Acids       Date:  2022-09-19       Impact factor: 10.183

Review 7.  Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.

Authors:  Sarah Shigdar; Lisa Agnello; Monica Fedele; Simona Camorani; Laura Cerchia
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.